What's in Stiefel, a GSK Company's pipeline?

Stiefel, a GSK Company has 30 drugs in our index: 15 marketed, 0 filed, 8 in Phase 3, 1 in Phase 2, 6 in Phase 1.

Which companies overlap with Stiefel, a GSK Company's portfolio?

Top competitors by shared drug class: Galderma R&D, LEO Pharma, GlaxoSmithKline, Actavis Inc., Sun Pharmaceutical Industries, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/stiefel-a-gsk-company.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Stiefel, a GSK Company — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Stiefel, a GSK Company pipeline: 15 marketed, 0 filed, 8 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

15 marketed 0 filed 8 Phase 3 1 Phase 2 6 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Epiduo Gel	Epiduo Gel	marketed
Olux-E Foam	Olux-E Foam	marketed
BENZOYL PEROXIDE/ CLINDAMYCIN	BENZOYL PEROXIDE/ CLINDAMYCIN	marketed	Topical antibiotic combination	Bacterial ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide)	Dermatology
0.25 % Miconazole Nitrate Ointment	0.25 % Miconazole Nitrate Ointment	marketed
Acitretin (also called U0279)	Acitretin (also called U0279)	marketed	Retinoid	Retinoid X receptor (RXR), Retinoid acid receptor (RAR)	Dermatology
Clobex lotion	Clobex lotion	marketed	Topical corticosteroid (Class I/Super-potent)	Glucocorticoid receptor	Dermatology
Clindamycin and BPO 5% gel	Clindamycin and BPO 5% gel	marketed	Topical antibiotic combination with keratolytic agent	Bacterial 50S ribosome (clindamycin); oxidative damage to bacterial cell membranes (BPO)	Dermatology
Duac Gel	Duac Gel	marketed	Topical antibiotic combination	Propionibacterium acnes (bacterial target); benzoyl peroxide acts via oxidative mechanism; clindamycin inhibits bacterial protein synthesis	Dermatology
Tretinoin Gel (tretinoin)	Tretinoin Gel (tretinoin)	marketed	Retinoid	Retinoic acid receptors (RAR-α, RAR-β, RAR-γ)	Dermatology
Benzoyl peroxide with clindamycin	Benzoyl peroxide with clindamycin	marketed	Topical antibiotic combination	Bacterial ribosomes (clindamycin); reactive oxygen species generation (benzoyl peroxide)	Dermatology
BENZOYL PEROXIDE/ ADAPALENE	BENZOYL PEROXIDE/ ADAPALENE	marketed	Retinoid + peroxide combination	Retinoic acid receptors (adapalene); bacterial cell oxidative stress (benzoyl peroxide)	Dermatology
Clobetasol propionate foam	Clobetasol propionate foam	marketed	Topical corticosteroid (Class I, super-potent)	Glucocorticoid receptor	Dermatology

Therapeutic area mix

Dermatology · 17
Infectious Disease / Dermatology · 1
Oncology · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Galderma R&D · 6 shared drug classes
LEO Pharma · 4 shared drug classes
GlaxoSmithKline · 3 shared drug classes
Actavis Inc. · 3 shared drug classes
Sun Pharmaceutical Industries, Inc. · 3 shared drug classes
Bausch Health Americas, Inc. · 2 shared drug classes
Federal University of São Paulo · 2 shared drug classes
GWT-TUD GmbH · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Stiefel, a GSK Company:

Cite this brief

Drug Landscape (2026). Stiefel, a GSK Company — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/stiefel-a-gsk-company. Accessed 2026-05-16.